Skip to main content
. 2018 Jan 23;2:PO.17.00160. doi: 10.1200/PO.17.00160

Fig 4.

Fig 4.

Plasma ALK (anaplastic lymphoma kinase) mutation kinetics during treatment. Figure illustrates the change in the allelic fraction of EML4-ALK and ALK mutations during sequential treatment with next-generation ALK inhibitors for (A) MGH987 and (B) MGH087. (C) ALK fusion and mutation kinetics before and after ablation of an oligometastasis (MGH989). The x-axis depicts days from initial plasma collection, whereas the y-axis reports allelic fraction. Criz, crizotinib.